Major known effects of the metabolic derangements of diabetes in haemostasis are induction of platelet-vascular activation by hyperglycaemia, the increase in fibrinogen, modification of fibrin substrate by glucose and hypofibrinolysis related to insulin resistance. The platelet effects are specifically expressed during high shear stress and may be relevant in particular for developing of micro-angiopathy. Hypofibrinolysis, increased fibrinogen and modifications of fibrin may aggravate microthrombosis and organ damage and contribute to precipitation of coronary and cerebral infarction. In addition to specific anti-diabetic medication to reduce the haemostatic effects, specific antiplatelet and profibrinolytic treatments may be relevant for reducing further the morbidity and mortality in diabetics for both micro- and macro-angiopathy.
Bierman ELAtherogenesis in diabetes. Arterioscl Thromb1992;12:647-55.
2.
Colwell JATreatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am2001;30:1011-30.
3.
Cominacini L. , Fratta PA, Garbin U. et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM; relation to metabolic control. Diabetologia1995;38:1122-4.
4.
Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S.Significance of chemokines and activated platelets in patients with diabetes . Clin Exp Immunol2000;121:437-43.
5.
Shouzu A., Nomura S., Hayakawa T. et al. Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus. Clin Appl Thromb Hemost2000;6:139-43.
6.
Omoto S., Nomura S., Shouzu A. et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron1999;81:271-7.
7.
Nomura S., Shouzu A., Omoto S. et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost1998;80:388-92.
8.
Elhadd TA, Kennedy G., Hill A. et al. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescent and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev1999 ;15:405-11.
9.
Nappo F., Esposito K., Cioffi M. et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J A Coll Cardiol2002;39:1145-50.
10.
van der Planken MG, Vertessen FJ, Vertommen J., Engelen W., Berneman ZN, De Leeuw I.Platelet prothrombinase activity, a final pathway platelet procoagulant activity, is overexpressed in type 1 diabetes: no relationship with mean platelet volume or background retinopathy. Clin Appl Thromb Hemost2000 ;6:65-8.
11.
Tooke JE, Shore AC, Cohen RA, Kluft C.Diabetic angiopathy: tracking down the culprits. J Diabetes Complications1996;10:173-81.
12.
Marfella R. , Esposito K., Giunta R. et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation2000; 101:2247-51.
13.
Ajzenberg N. , Denis CV, Veyradier A., Girma JP, Meyer D., Baruch D.Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic microangiopathy. Thromb Haemos2002;87:808-11.
14.
Kharbanda RK , Walton B., Allen M. et al. Prevention of inflammation-induced endothelial dysfunction. A novel vascula-protective action of asprin. Circulation2002;105:2600-04.
15.
Otsuki M., Saito H., Sumitani S., Kouhara H., Kurabayashi M., Kasayama S.Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis2001;158:121-8.
16.
Martin S., van den Engel NK, Vinke A., Heidenthal E., Schulte B., Kolb H.Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. J Autoimmune2001;17:109-17.
17.
Nishimura M. , Obayashi H., Maruya E. et al. Association between type 1 diabetes age-at-onset and intercellular adhesion moleculae-1 (ICAM-1) gene polymorphism . Hum Immunol2000;61:507-10.
18.
Konieczkowski M., Skrinska VAIncreased synthesis of thromboxane A (2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids2001;65:133-8.
19.
Kaplar M., Kappelmayer J., Veszpremi A., Szabo K., Udvardy M.The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets2001;12:419-22.
20.
Desfaits AC , Serri O., Renier G.Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care1998;21:487-93.
21.
Cominacini L., Garbin U., Pasini AF et al. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhes Commun1999;7:223-31.
22.
The DAMAD Study Group.Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes1989;38:491-8.
23.
Hopper AH, Tindall H., Davies JAAdministration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy . Nephrol Dial Transplant1989 ;4:140-3.
24.
Rubtsova AL , Ametov AS, Strakhov VVThe use of ticlid in diabetic retinopathy . Ter Arkh1997;69:19-21.
25.
Esmatjes E. , Maseras M., Gallego M., Coves MJ, Conget I.Effect of treatment with an inhibitor of platelet aggregation on the evaluation of background retinopathy: 2 years of follow up. Diabetes Res Clin Pract1989; 7:285-91.
26.
Myrup B., Rossing P., Jensen T., Gram J., Kluft C., Jespersen J.Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy . Fibrinolysis Proteolysis1996 ;10:331-5.
27.
Bruttomesso D., Iori E., Kiwanuka E. et al. Insulin infusion normalizes fasting and post-prandial albumin and fibrinogen synthesis in type 1 diabetes mellitus . Diabet Med2001;18:915-20.
28.
Ceriello A. , Taboga C., Giacomello R. et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes1994;43:430-2.
29.
Avellone G. , di Garbo V., Crdova R. et al. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients. Metabolism1997;46:930-4.
30.
Myrup B., Jensen T., Gram J., Kluft C., Jespersen J., Deckert T.No effect of unfractionated or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy . Diabetes Care1997;20:1615-19.
31.
D'Elia JA, Weinrauch LA, Gleason RE et al. Fibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complications . Arch Intern Med2001;161: 98-101.
32.
Maat de MPM.Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann NY Acad Sci2001;936:509-21.
33.
Schut NH, van Arkel EC, Hardeman MR, Bilo HJ, Michels RP, Vreeken J.Blood and plasma viscosity in diabetes: possible contribution to late organ complications?Diabetes Res1992;19:31-5.
34.
Sandhagen B. , Ewald U., Tuvemo T.Haemorheology in insulin-dependent diabetes is still normal five years after onset of the disease. Acta Paediatr1997;418(suppl):21-3.
35.
Richter WO, Jahn P., Jung N., Nielebock E., Tachezy H.Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience. Ther Apher2001;5:335-9.
36.
Koll RA, Klinkmann J., Richter WORheoSorb: a specific adsorber for fibrinogen elimination in clinical situations with impaired rheology. Artif Organs2002;26:145-51.
37.
Boeri D., Maiello M., Lorenzi M.Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes2001;50:1432-9.
38.
Bent-Hansen L.Whole body capillary exchange of albumin. Alterations in diabetic microangiopathy. Dan Med Bull1997;44:40-55.
39.
Murakami T. , Egawa H., Komiyama Y., Masuda M., Murata K.Increased accumulation of nonenzymatically glycated fibrinogen in the renal cortex in rats. Thromb Res1990;58:23-33.
40.
Jorneskog G. , Egberg N., Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologica1996;39:1519-23.
41.
Nair CH, Azhar A., Wilson JD, Dhall DPStudies on fibrin network structure in human plasma. Part II. Clinical application: diabetes and antidiabetic drugs. Thromb Res1991;64:477-85.
42.
Brownlee M. , Vlassara H., Cerami A.Nonenzymatic glycosilation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes1983;32: 680-4.
43.
Mirshahi M. , Soria J., Soria C., Bertrand O., Mirshahi M., Basdevant A.Glycosilation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb Res1987;48:279-89.
44.
Dhall DP, Nair CHEffects of gliclazide on fibrin network. J Diabetes Complications1994;8:231-4.
45.
Williams S. , Fatah K., Ivert T., Blomback M.The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis1995;6:718-25.
46.
Standeven KF , Ariens RA, Whitaker P., Ashcroft AE, Weisel JW, Grant PJThe effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation . Diabetes2002;51:189-97.
47.
Kohler HP, Grant PJThe role of factor XIIIVal34Leu in cardiovascular disease. QJM1999;92:67-72.
48.
Kohler HP, Grant PJPlasminogen-activator inhibitor type 1 and coronary artery disease . N Engl J Med2000;342:1792-801.
49.
Mansfield MW , Stickland MH, Grant PJPlasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost1995;74:1032-4.
50.
Kluft C.Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): conditions and therapeutic targets. Fibrinolysis1994;8(suppl 2):1-7.
51.
Juhan-Vague I., Roul C., Alessi MC, Ardissone JP, Heim M., Vague P.Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemost1989;61:370-3.
52.
Juhan-Vague I., Alessi MC, Vague P.Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis . Diabetologia1991;34:457-62.
53.
Riese H., Vrijkotte TGM, Meijer P., Kluft C., de Geus EJC.Covariance of metabolic and hemostatic risk indicators in men and women. Fibrinolysis & Proteolysis2001 ;15:9-20.
54.
Pandolfi A. , Cetrullo D., Polishuck R. et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects . Arterioscler Thromb Vasc Biol2001;21;1378-82.
55.
Aso Y., Matsumoto S., Fujiwara Y., Tayama K., Inukai T., Takemura Y.Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1 . Metabolism2002;51:471-6.
56.
Zeitler P., Thiede A., Muller HLProspective study on plasma clotting parameters in diabetic children - no evidence for specific changes in coagulation system. Exp Clin Endocrinol Diabetes2001;109:146-50.
57.
Asakawa H., Tokunaga K., Kawakami F.Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications2000;14:121-6.
Gabazza EC, Takeya H., Deguchi H. et al. Protein C activation in NIDDM patients. Diabetologia1996;39:1455-61.
60.
Kario K., Matsuo T., Kobayashi H., Matsuo M., Sakata T., Miyata T.Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria . Arterioscler Thromb Vasc Biol1995;15:1114-20.
61.
Ceriello A. , Taboga C., Tonutti L. et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia1996;39:469-73.
62.
Grant PJThe effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes care1996;19:648-54.
63.
Gregorio F. , Ambrosi F., Manfrini S. et al. Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin . Diabet Med1999 ;16:1016-24.
64.
Anfosso F., Chomiki N., Alessi MC, Vague P., Juhan-Vague I.Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest1993;91: 2185-93.
65.
Nagi DK, Yudkin JSEffects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care1993;16:621-9.
66.
Diamant M., Brussaard HE, Princen HMG et al. Glycated LDL is associated with fibrinolysis in women with type 2 diabetes. Diabetes1999; 48(S1):A1611.
67.
Ren S., Lee H., Hu L., Lu L., Shen GXImpact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. J Clin Endocrinol Metab2002;87:286-91.
68.
Knobl P., Schernthaner G., Schnack C. et al. Haemostatic abnormalities persist despite glycemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost1994;71:692-7.
69.
Avellone G. , di Garbo V., Cordova R. et al. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients. Metabolism1997;46:930-4.
70.
Nagi DK, Yudkin JSEffects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care1993;16:621-9.
71.
Grant PJ, Stickland MH, Booth NA, Prentice CRMetformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med1001;8:361-5.
72.
Vague P., Juhan-Vague I., Alessi MC, Badier C., Valadier J.Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost1987;57:326-8.
73.
Lee AJ, MacGregor AS, Hau CM et al. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh Artery Study. Br J Haemat1999;105:648-54.
